Ocrevus Injection
Product Images NDC 50242-150

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Ocrevus (NDC 50242-150). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Ocrevus 01)

This text appears to be a mix of numerical values, medication names, and statistical data related to health outcomes. The medications mentioned are REBIF and EVUS, which may be used to treat conditions that have led to disability progression. The text also provides a percentage that notes a reduction in the risk of a particular health outcome, as well as a chart displaying the number of patients and their risk levels over time. However, the purpose and context of this information are unclear.*

FDA Label Image

Figure 2 (Ocrevus 02)

FDA Label Image

Principal Display Panel (300 mg/10 mL Vial Carton)

NDC 50242-150-01 is a medication called Ocrevus® (ocrelizumab). It is administered through intravenous infusion and comes in a single-dose vial that must be diluted. Any unused portion of the drug must be discarded. Pharmacists are advised to provide patients with the accompanying Medication Guide.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.